.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
US Department of Justice
Cantor Fitzgerald
Chinese Patent Office
Cerilliant
Fish and Richardson
Novartis
Teva
Deloitte
AstraZeneca

Generated: November 24, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,988,001

« Back to Dashboard

Which drugs does patent 7,988,001 protect, and when does it expire?


Patent 7,988,001 protects STRIVERDI RESPIMAT, COMBIVENT RESPIMAT, STIOLTO RESPIMAT, and SPIRIVA RESPIMAT, and is included in four NDAs.

Protection for SPIRIVA RESPIMAT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-five patent family members in thirty-six countries.

Summary for Patent: 7,988,001

Title:Container provided with a pressure equalization opening
Abstract: A process for producing a container comprising an outer container, an inner bag disposed therein and a pressure equalisation opening disposed in the outer container, and a container produced according to this process, is described, wherein a pre-moulding, comprising two coaxial tubes, is first produced by co-extrusion with the help of a blow mould and with an outwardly-projecting base seam being formed. The process forms a pressure equalisation opening in the outer container without endangering the integrity of the container, wherein a lower wastage rate and higher productivity are achieved. To do this, the base seam is partially cut off and a force which acts in the direction of the seam is introduced into the pre-moulding, which has a temperature of 40 degrees C. to 70 degrees C., which force breaks open and plastically deforms the base seam so that a pressure equalisation opening is formed in the base area.
Inventor(s): Kuehn; Torsten (Ingelheim, DE), Metzger; Burkhard Peter (Ingelheim, DE)
Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG (Ingelheim am Rhein, DE)
Application Number:11/778,715
Patent Claim Types:
see list of patent claims

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Boehringer Ingelheim
STRIVERDI RESPIMAT
olodaterol hydrochloride
SPRAY, METERED;INHALATION203108-001Jul 31, 2014RXYesYes► Subscribe► SubscribeY
Boehringer Ingelheim
COMBIVENT RESPIMAT
albuterol sulfate; ipratropium bromide
SPRAY, METERED;INHALATION021747-001Oct 7, 2011RXYesYes► Subscribe► SubscribeY
Boehringer Ingelheim
STIOLTO RESPIMAT
olodaterol hydrochloride; tiotropium bromide
SPRAY, METERED;INHALATION206756-001May 21, 2015RXYesYes► Subscribe► SubscribeY
Boehringer Ingelheim
SPIRIVA RESPIMAT
tiotropium bromide
SPRAY, METERED;INHALATION021936-002Sep 15, 2015RXYesNo► Subscribe► SubscribeY
Boehringer Ingelheim
SPIRIVA RESPIMAT
tiotropium bromide
SPRAY, METERED;INHALATION021936-001Sep 24, 2014RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,988,001

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany100 17 443Apr 07, 2000
Germany100 17 443Apr 7, 2000

Non-Orange Book Patents for Patent: 7,988,001

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,503,440 Process for making a container with a pressure equalization opening and containers produced accordingly► Subscribe
7,451,884Container provided with a pressure equalization opening► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,988,001

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina027775► Subscribe
Austria275472► Subscribe
Australia6209301► Subscribe
Bulgaria107052► Subscribe
Bulgaria64671► Subscribe
Brazil0109859► Subscribe
Canada2403148► Subscribe
China1195621► Subscribe
China1419491► Subscribe
Czech Republic20023326► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Johnson and Johnson
Fuji
Citi
McKinsey
McKesson
Chinese Patent Office
Covington
Farmers Insurance
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot